Hematology NewsDaratumumab, elotuzumab eyed for initial treatment of myelomaMay 4, 2017Multiple MyelomaLymphoma & Plasma Cell Disorders
Hematology TimesFDA issues warnings about illegal ‘anticancer’ productsApril 26, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaPharmacyRelated Issues
Hematology TimesA spouse’s cancer diagnosis can lower household incomeApril 25, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple Myeloma
Hematology NewsLenalidomide maintains posttransplant remissions in myelomaApril 24, 2017Multiple Myeloma
Hematology TimesHealth Canada expands approval of daratumumab in MMApril 18, 2017Multiple MyelomaPharmacy
Hematology TimesInhibitor exhibits activity against hematologic malignanciesApril 18, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology NewsMinimal residual disease eyed for myeloma managementApril 14, 2017Multiple MyelomaLymphoma & Plasma Cell Disorders
Hematology NewsExpanded drug combinations produce best myeloma inductionApril 14, 2017Multiple MyelomaLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
Hematology TimesCAR T-cell therapy demonstrates efficacy in mice with MMApril 14, 2017Multiple Myeloma
Hematology TimesWeighing risks, benefits of autologous HSCT in MMApril 10, 2017Multiple MyelomaTransplantation
Hematology NewsTransplantation plus VRD tops VRD alone in myelomaApril 5, 2017Multiple MyelomaLymphoma & Plasma Cell DisordersCellular Therapy
